Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Nyxis Neurotherapies Inc
Profile last edited on: 9/2/2023      CAGE: 47FQ0      UEI: ----------

Business Identifier: Drug Development
Year Founded
1999
First Award
2005
Latest Award
2006
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1801 Maple Avenue
Evanston, IL 60208
   (847) 491-4802
   j-moskal@northwestern.edu
   www.nyxis.com
Location: Single
Congr. District: 09
County: Cook

Public Profile

Nyxis Neurotherapies, Inc. is a research-oriented biotechnology company focused on the development and commercialization of therapeutics that target and alleviate neurological disorders. Nyxis uses its proprietary, patented drug development platform, MADCP, to produce neuro-therapeutic compounds.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
1
Conversion Rate
50.00%
Phase I Dollars
$378,454
Phase II Dollars
$239,204
Total Awarded
$617,658

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2006 2 NIH $489,204
Project Title: Novel therapeutics for learning and memory disorders
2005 1 NIH $128,454
Project Title: Novel therapeutics for chronic pain

Key People / Management

  Joseph Moskal -- President

  Mary Henske -- V.P. Strategic Planning

  Jan E Leestma -- Chief Medical Officer/Co-founder

  Paul L Wood

Company News

There are no news available.